HOME >> BIOLOGY >> NEWS
Enzyme mimetic reduces tissue damage in colitis animal study

ings, or fistulas, develop in the intestine. Because of difficulty diagnosing the disease, the estimated incidence of these disorders varies widely. Crohns disease, however, is now considered to be the second most common chronic inflammatory disorder, after rheumatoid arthritis.

In the study, researchers evaluated the effects of M40403 on inflammatory bowel disease and symptoms. Comparing treated animals to untreated animals:

Colonic tissue damage, as evaluated histologically, was substantially reduced.

Inflammation was reduced, as confirmed by a significant increase in both colon and spleen weights.

TNF-a and IL-1b levels were reduced to near normal.

Adhesion molecule expression in the intestinal wall was reduced.

Diarrhea and body weight loss were markedly reduced.

The results of this study echo those from another MetaPhore study looking at rheumatoid arthritis published this month in Arthritis & Rheumatism. In that study, an SOD mimetic was highly effective, not only at treating inflammation, but also preventing joint damage and reducing elevated cytokine levels to near normal in animal models of arthritis. These preclinical findings bode well for the potential of SOD mimetics as clinical candidates for inflammatory bowel disease, including Crohns disease and ulcerative colitis, said Daniela Salvemini, Ph.D., MetaPhores Vice President of Pharmacology and the principal investigator. The protective effects observed in this model appear to be a result of the SOD mimetics ability to inhibit superoxide and cytokine production, consistent with earlier research and our recent positive preclinical outcomes in models of arthritis.


'"/>

Contact: Punnie Donohue
pdonohue@kupperparker.com
314-290-2014
Kupper Parker Communications
12-Dec-2001


Page: 1 2

Related biology news :

1. Enzyme maintaining chromosome ends is linked to bone cancer recurrence, decreased survival
2. Enzyme activation appears key in helping internal clock tell night from day
3. Enzyme fully degrades mad cow disease prion
4. Enzyme revealed that is key to funguss ability to breach immune system
5. Enzyme discovery sheds light on causes of rare disease, cancer
6. Enzyme could overcome industrial bleaching waste problems
7. Enzyme controls good cholesterol
8. Enzyme discovery to benefit homeland security, industry
9. Enzyme could aid cancer fight
10. Enzyme once thought harmful to Alzheimers patients now appears key to future treatment
11. Enzyme studies at Brookhaven Lab may lead to new antiviral agents

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/29/2019)... ... , ... In the wake of the success of IBBL’s ... biobanks was launched in July 2018, in an agreement between IBBL, the International ... Biotech Association (BBCMBA). The one-year pilot programme offered two testing schemes: ‘DNA quantification ...
(Date:3/27/2019)... ... March 27, 2019 , ... NDA Partners Chief Executive Officer ... Health & Pharma Biotechnology Award as the Best Life Sciences Management & Contract ... individuals and companies whose accomplishments have proved evidence of extensive expertise and skills, ...
(Date:3/25/2019)... , ... March 25, 2019 , ... ... Visikol, a contract research organisation focused on advancing drug discovery, have announced a ... imaging. , Tissue clearing methods, which are essential to get a better view ...
Breaking Biology News(10 mins):
(Date:4/16/2019)... ... 16, 2019 , ... On April 24th, the Federal Laboratory ... Center for Environmental Health Research (USACEHR), with an award for their cooperative effort ... veteran-owned company located at the Frederick Innovative Technology Center, Inc. (FITCI) on Metropolitan ...
(Date:4/10/2019)... ... April 10, 2019 , ... After more than three months of renovation, Lajollacooks4u ... equipped with updated appliances and modern lighting and fixtures, and will provide additional workspace ... “We’ve seen tremendous growth in the demand for our team-building events and cooking classes ...
(Date:4/8/2019)... (PRWEB) , ... April 08, 2019 , ... US ... investors a $15 million preferred equity investment in the privately held pharmaceutical company, S1 ... leading drug, Lorexys, is targeted at female hypoactive sexual dysfunction disorder and is ready ...
(Date:3/27/2019)... ... March 26, 2019 , ... A leader in the field of Regenerative ... across the United States and Canada since 2004. The primary indications for VetStem ... in the dog, cat, and horse. Recently, VetStem teamed up with the ...
Breaking Biology Technology:
Cached News: